Mendus
4.21 SEK
+1.45 %
Less than 1K followers
IMMU
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Mendus
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.9 | 0.0 | 3.4 | ||||
| growth-% | 10,803.2 % | ||||||
| EBITDA | -132.3 | -86.0 | -130.1 | -133.7 | -100.7 | -130.7 | - |
| EBIT | -132.3 | -86.0 | -130.1 | -133.7 | -100.7 | -130.7 | -113.5 |
| Profit before taxes | -134.0 | -89.2 | -133.4 | -138.8 | -101.6 | -128.4 | -113.3 |
| Net income | -134.0 | -89.2 | -133.4 | -138.8 | -101.6 | -128.4 | -113.3 |
| EPS | -26.76 | -9.89 | -12.32 | -12.90 | -4.40 | -2.64 | -2.17 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -14,817.9 % | -419,677.4 % | -3,955.3 % | ||||
| EBIT-% | -14,817.9 % | -419,677.4 % | -3,955.3 % | ||||
| ROE | -49.1 % | -13.5 % | -20.3 % | -27.0 % | -14.4 % | -19.9 % | -19.4 % |
| ROI | -44.1 % | -12.2 % | -18.5 % | -22.4 % | -13.4 % | -18.4 % | -18.0 % |